7 RESULTS
COMMENT The results of the 18-month study with BAN2401 in 856 subjects with prodromal AD or mild AD has raised a lot of interest and prudent hope. We know very little about the trial and will learn more in a couple of weeks at AAIC. In the meantime, will can make ...
COMMENT Chen and colleagues have proposed a new pathophysiological role for AICD in PD pathogenesis. They showed that LRRK2 phosphorylated APP at Thr668, and that this further promoted the nucleus transcriptional activity of AICD, and its translocation to the ...
COMMENT Lilly researchers set up EXPEDITION3 when a subgroup analysis of EXPEDITION1 and EXPEDITION2 trials suggested a benefit only for patients with mild disease. Why did EXPEDITION3 not confirm apparent positive findings of the two prior trials in mildly ...
COMMENT In this paper on the aducanumab Phase 1b study in prodromal and mild AD patients, the data on plaque removal are quite encouraging. As pointed out on AlzForum, the initial positive cognitive data need to be confirmed in the ongoing Phase 3 studies, and I ...
COMMENT This study was well-conducted and is elegant because it shows consistent effects of the drug citalopram in transgenic mice and in humans. Regarding the potential use of citalopram in Alzheimer’s disease patients, Mark Mattson correctly points out that ...
COMMENT The community as a whole—independent researchers, colleagues and competitors alike—are eagerly awaiting a successful AD trial, hence there is widespread disappointment about the results of this 52-week study of PBT2 in 42 prodromal AD or mild AD patients. ...
COMMENT Soluble β amyloid has a beneficial physiological role for the normal functioning of neurons. In the AD brain, the increase in soluble β amyloid concentrations, mainly via a decrease in its clearance, could simply represent the brain's attempt to ...
